About

Michael Evans-Brown is a specialist in early warning, risk assessment, and public health responses to emerging drug threats such as new psychoactive substances (NPS).

Since 2012, he has worked at the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) where he is programme manager for risk assessment and risk communication in the team that is responsible for the European Union Early Warning System and risk assessment of new psychoactive substances.

Prior to joining the EMCDDA, Mike worked at Liverpool John Moores University, as a senior researcher in emerging drugs issues with a focus on the use of human enhancement drugs in society. He was also responsible for coordinating the United Kingdom’s early warning system on new psychoactive substances.

Mike has published extensively on new psychoactive substances and other emerging drug issues. He tweets @mevansbrown

Publications

Responding to new psychoactive substances in the European Union: Early warning, risk assessment, and control measures.
Evans-Brown M, Sedefov R. Handb Exp Pharmacol. 2018;252:3-49.
Journal site | Download this paper

Fentanils: a serious threat to public health.
Mounteney J, Griffiths P, Sedefov R, Evans-Brown M. Addiction. 2019.

Responding to new psychoactive substances in the European Union: Early warning, risk assessment, and control measures.
Evans-Brown M, Almeida A, Gallegos A, Christie R, Jorge R, Danielsson HV, le Ruez T, Sedefov R. In: Chemical Health Threats: Assessing and Alerting. Edited by: Duarte-Davidson R, et al. Royal Society of Chemistry. 2018.

Fentanils: A serious threat to public health in Europe.
Evans-Brown M, Almeida A, Gallegos A, Christie R, Jorge R, Danielsson HV, le Ruez T, Sedefov R. In: Chemical Health Threats: Assessing and Alerting. Edited by: Duarte-Davidson R, et al. Royal Society of Chemistry. 2018.

Assessing the toxicological significance of new psychoactive substances in fatalities.
Elliott S, Sedefov R, Evans-Brown M. Drug Test Anal. 2018;10(1):120–6.
PubMed entry | Journal site

Acryloylfentanyl (acrylfentanyl), a recently emerged new psychoactive substance: a comprehensive review.
Ujváry I, Jorge R, Christie R, Le Ruez T, Danielsson HV, Kronstrand R, Elliott S, Gallegos A, Sedefov R, Evans-Brown M. Forensic Tox. 2017;35(2):232–43.
PubMed entry | Journal site

New psychoactive substances: driving greater complexity into the drug problem.
Evans-Brown M, Sedefov R. Addiction. 2017;112(1):36–8.
PubMed entry | Journal site

Legal controls of psychoactive substances in Europe.
Hughes B, Evans-Brown M, Sedefov R. Handbuch Psychoaktive Substanzen. 2016. Springer Berlin Heidelberg.

Anabolic steroids detected in bodybuilding dietary supplements – a significant risk to public health.
Abbate V, Kicman AT, Evans-Brown M, McVeigh J, Cowan DA, Wilson C, Coles SJ, Walker CJ. Drug Test Anal. 2015;7(7):609–18.

The new drug phenomenon.
Brandt SD, King LA, Evans-Brown M. Drug Test Anal. 2014;6(7-8):587–97.
PubMed entry | Journal site

Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.
Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A. Drug Test Anal. 2015;7(2):164–72.

Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking.
Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, Parry JV, Ncube F. Epidemiol Infect. 2015;143(1):132–40.

Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?
Evans-Brown M, Kimergård A, McVeigh J, Chandler M, Brandt SD. BMJ. 2014;348:g1476.

The (mis)use of psychoactive medicines: getting the balance right in complex systems.
Griffiths P, Evans-Brown M, Sedefov R. Addiction. 2014;109(2):182–3.

Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study.
Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, Croxford S, Beynon CM, Parry JV, Bellis MA, Ncube F. BMJ Open. 2013;3(9):e003207.
PubMed entry | Journal site

Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the Information Age.
Griffiths P, Evans-Brown M, Sedefov R. Addiction. 2013;108(10):1700–3.

Human enhancement drugs and the pursuit of perfection.
McVeigh J, Evans-Brown M, Bellis MA. Adicciones. 2012;24(3):185–90.

Social, policy, and public health perspectives on new psychoactive substances.
Sumnall HR, Evans-Brown M, McVeigh J. Drug Test Anal. 2011;3(7-8):515–23.

Should “legal highs” be regulated as medicinal products?
Evans-Brown M, Bellis MA, McVeigh J. BMJ. 2011;342:d1101.

Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market.
Evans-Brown M, Kimergård A, McVeigh J. Drug Test Anal. 2009;1(7):323–6.

Use of melanotan I and II in the general population.
Evans-Brown M, Dawson RT, Chandler M, McVeigh J.BMJ. 2009;338:b566.

Injecting human growth hormone as a performance-enhancing drug—perspectives from the United Kingdom.
Evans-Brown M, McVeigh J. J Subst Use. 2009;14:267–88.

The dire consequences of doping?
Evans-Brown M, Dawson R, McVeigh J. Lancet. 2008;372(9649):1544.

Presentations

Non-medical use of psychoactive medicines. European situation and response.
Evans-Brown M. 2019 International Conference on Narcotics: Safe Use and Management. Taipei City, Taiwan, 4 September 2019.